Clinical trial · Interventional
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
NCT01733004CI-TRIAL-00023366completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MM-141 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Arm A
- description
- MM-141 monotherapy
- interventionNames
- Drug: MM-141
- type
- EXPERIMENTAL
- label
- Arm B
- description
- MM-141 and Everolimus
- interventionNames
- Drug: MM-141
- type
- EXPERIMENTAL
- label
- Arm C
- description
- MM-141 and Abraxane and Gemcitabine
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced malignant solid tumors for which no curative therapy exists that has recurred or pgrogressed following standard therapy * Eighteen years of age or above * Able to understand and sign an informed consent (or have a legal representative who is able to do so) * Measurable disease according to RECIST v1.1 * ECOG Performance Score of 0 or 1 * Adequate bone marrow, hepatic, renal and cardiac function * Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-141 Exclusion Criteria: * Active infection or fever \> 38.5°C during screening visits or on the first scheduled day of dosing * Symptomatic CNS disease * Received other recent antitumor therapy * Pregnant or breast feeding
References
Publications (0)
Data not yet available
No reference posted for this study.